Benefits of T-DXd for HER2-Low Breast Cancer Continue.

Published Date: 11 Nov 2023

When compared to physician's choice of treatment (TPC), trastuzumab deruxtecan (T-DXd) offered patients with advanced breast cancer and low HER2 expression a sustained clinically meaningful improvement.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot